Perspective · for clinicians

EGFR-mutant NSCLC after osimertinib: the 2026 phase 3 evidence, ahead of the 14 Nov FDA decision

11/9/2026 · 4 min read · updated 9 Nov 2026

Bottom line

Platinum–pemetrexed is still the common comparator and still the default where nothing else is accessible. Three of the four new options are not approved anywhere outside China; none is approved by CDSCO.

Progression on osimertinib is the most common decision point in EGFR-mutant NSCLC. For years the answer was platinum–pemetrexed. In 2026 four randomised phase 3 trials have reported against that same comparator, and the FDA acts on one of them (ivonescimab, HARMONi) on 14 November. This note lines them up. Cross-trial comparison is hazardous: populations, biomarker selection and follow-up differ.

The four trials at a glance

Trial	Experimental arm	Selection	n	PFS, months (HR)	OS so far
SAFFRON (global; NEJM)	Osimertinib + savolitinib (MET TKI)	MET overexpression and/or amplification after osimertinib	—	7.6 vs 5.4 (0.55)	17.8 vs 12.9 mo, HR 0.68 (p=0.01)
HERON-Lung01 (China; Lancet)	Ruzaltatug rezetecan (HER3 ADC)	Ex19del/L858R after any EGFR TKI	498	8.3 vs 5.4 (0.47)	Immature, HR 0.70 (0.43–1.14)
PANKU-Lung01 (China; Lancet)	Izalontamab brengitecan (EGFR×HER3 bispecific ADC)	After third-generation EGFR TKI, chemo-naive	432	11.1 vs 5.7 (0.40)	Immature; 12-mo OS 83.0% vs 72.9%
HARMONi (global)	Ivonescimab (PD-1×VEGF) + platinum–pemetrexed	After third-generation EGFR TKI	—	Significant (see our November FDA note)	Primary HR 0.79 (0.62–1.01), not significant

All comparators: platinum + pemetrexed, then pemetrexed maintenance (HARMONi: placebo + platinum doublet). “—” means we have not verified the exact number for this note.

Median PFS: new agent vs platinum–pemetrexed (months)

SAFFRON7.6 mo

HERON-Lung018.3 mo

PANKU-Lung0111.1 mo

Control arms: 5.4, 5.4 and 5.7 months. Different populations and follow-up; not a head-to-head comparison.

SAFFRON — the biomarker-driven option

• Osimertinib continued plus savolitinib, in tumours with MET overexpression, amplification or both.
• PFS HR 0.55 (0.42–0.72); 12-month PFS 36% vs 10%. ORR 51% vs 27%.
• Only trial of the four with a statistically significant OS gain: HR 0.68 (0.50–0.91).
• Cost of the gain: peripheral oedema 49%; serious AEs 41% vs 28%; fatal AEs 7% vs 0%.
• Needs a tissue MET test (IHC and/or amplification) at progression. Already covered in depth in our ESMO 2026 Presidential Symposium II note.

HERON-Lung01 — HER3 ADC (ruzaltatug rezetecan, SHR-A2009)

• 62 sites in China; ages 18–75; 8.0 mg/kg IV every 3 weeks.
• BICR PFS 8.3 vs 5.4 months, HR 0.47 (0.36–0.60), at a median follow-up of only 7.7 months.
• ORR 60.0% vs 34.3%; median DoR 8.5 vs 4.4 months.
• Grade ≥3 TRAEs 41% vs 39% (mainly neutropenia); discontinuation for TRAEs 1% in each arm; ILD 2.4% (one grade 3).
• OS immature (HR 0.70, CI crosses 1) and will be diluted by 19.4% crossover.

PANKU-Lung01 — EGFR×HER3 bispecific ADC (izalontamab brengitecan, iza-bren)

• 73 sites in China; 2.5 mg/kg IV on days 1 and 8 every 3 weeks.
• BICR PFS 11.1 vs 5.7 months, HR 0.40 (0.31–0.51); 12-month PFS 46.5% vs 14.4%.
• Larger effect with exon 19 deletion (HR 0.31) than L858R (HR 0.59).
• ORR 60.2% vs 34.5%. Interim OS: median not reached vs 19.4 months.
• More toxic: grade ≥3 TRAEs 79% vs 62% (mostly haematological), and day 1 + day 8 dosing doubles infusion visits.
• Primary analysis was modified ITT (treated patients only).

What to watch on 14 November

FDA must decide whether a PFS win plus a non-significant primary OS (HARMONi) is enough for ivonescimab. That decision will signal how regulators may treat the two Chinese ADC trials, which so far also rest on PFS with immature OS.

Practical reading today

• Re-biopsy at progression still matters: MET status selects for SAFFRON-type therapy; transformation to small-cell histology changes everything.
• Where none of the new agents is accessible, platinum–pemetrexed remains a valid standard. Amivantamab + carboplatin–pemetrexed (MARIPOSA-2; FDA Sep 2024) and datopotamab deruxtecan (FDA accelerated approval Jun 2025) are the other approved routes in the US.
• PFS gains of 3–5 months with immature OS should be weighed against toxicity and visit burden.

Sources

1. The Lancet — HERON-Lung01: ruzaltatug rezetecan vs chemotherapy, interim analysis (Xu et al, published 26 Oct 2026; NCT06671379)
2. The Lancet — PANKU-Lung01: izalontamab brengitecan vs platinum chemotherapy (NCT06382116)
3. The ASCO Post — HERON-Lung01 HER3-directed ADC prolongs PFS (ESMO 2026 LBA72)
4. OncLive — PANKU-Lung01 ORR, interim OS and safety detail (ESMO 2026)
5. The ASCO Post — SAFFRON: osimertinib + savolitinib after osimertinib progression (ESMO 2026 LBA6; NEJM)
6. Summit Therapeutics — FDA accepts ivonescimab BLA, PDUFA 14 Nov 2026
7. Summit Therapeutics — updated HARMONi overall survival (WCLC 2026)
8. FDA — Oncology/hematologic malignancies approval notifications (amivantamab + carboplatin–pemetrexed, Sep 2024; datopotamab deruxtecan EGFR NSCLC, Jun 2025)

Educational summary, not medical advice. Opinions are labelled as such and are the author's own. Approvals and availability in India (CDSCO) may differ from the US/EU.

← Back to blog